As a clinician formally trained in chiropractic and family nursing practice, I have spent years integrating conservative musculoskeletal care with orthobiologic therapeutics grounded in modern evidence-based methods. I’m Dr. Jimenez, DC, FNP-APRN, and in this educational post, I summarize the latest clinical strategies and research trends that guide how I use platelet-rich plasma (PRP), autologous protein concentrates, laser therapy, and shockwave therapy for tendon, joint, and bone-related conditions—focusing on the practical, step-by-step reasoning behind each choice. Over the past decade, the clinical and scientific landscape has shifted dramatically: dedicated organizations like the Interventional Orthobiologics Foundation and the Biologics Association have fostered rigorous, standardized, and patient-centered research methodologies. The result is stronger evidence, clinically meaningful outcomes, and better protocols based on modern bench research and validated patient-reported outcomes (PROs). I aim to offer clinicians and informed patients an approachable yet rigorous window into the clinical decision-making processes that balance efficacy, safety, regulation, and patient experience.
I begin with a granular discussion of how I select and dose protein concentrate (PC) alongside PRP for small- and large-volume joint injections, specifying the rationale for ratios (e.g., 3:1 to 4:1 in volume-restricted joints and 1:1 in larger joints) and when I avoid PC in tendinous applications due to cost-benefit and volume concerns. We will then challenge outdated notions about PRP composition, examining compelling evidence that a small, controlled inclusion of the upper layer of red blood cells—the “red top”—can significantly increase platelet and crucial mononuclear cell concentrations.
Next, I dive into whether and when to employ shockwave therapy following biologic interventions, distinguishing its utility in recalcitrant tendon disorders and bone marrow edema/lesions, while underscoring laser therapy for tenuous, structurally vulnerable tendon presentations. We will transition into the practicalities of application, from appropriate injectate volumes for various joints to the “joint as an organ” concept, which advocates for treating the entire functional joint unit.
From there, I transition to pragmatic practice insights on ethically growing an orthobiologics program without inviting regulatory risk. I outline a framework—the “three-legged stool” of patient trust, regulatory compliance, and practice growth—and detail how the FDA governs products/devices and the FTC governs advertising claims, complemented by oversight from state medical boards. This section offers actionable steps to audit communications and champions evidence-based, balanced messaging over hype. I further articulate a risk-tier framework—the Green Zone, Yellow Zone, and Red Zone—to guide decision-making.
This educational post culminates with detailed procedural walkthroughs, a real-world case study on lateral epicondylitis, and an in-depth look at patient preparation and post-procedure care. The concluding sections—Summary, Conclusion, and Key Insights—recap the central methodologies and reasoning, with explicit dates to anchor timelines and keep the content practically useful. My commitment is to clarity, transparency, and adherence to evolving science—recognizing that best practices grow stronger through ongoing discovery and honest dialogue. This is not medical advice; it is an educational synthesis designed to help clinicians and informed patients understand the mechanisms, methods, and clinical reasoning behind autologous orthobiologic treatments.
Table of Contents
Greetings, and welcome to our educational series on advanced regenerative medicine techniques. I’m Dr. Jimenez, and I’m honored to share my clinical insights and the latest research from our field with you. In my roles as a Doctor of Chiropractic (DC) and a Family Nurse Practitioner (FNP-APRN), I’ve dedicated my practice to integrating evidence-based, cutting-edge therapies to help patients find lasting relief and functional restoration. My approach is rooted in a deep understanding of human physiology and a commitment to leveraging the body’s intrinsic healing capabilities. Today, we’re going to embark on a deep dive into the fascinating world of Platelet-Rich Plasma (PRP) therapy, a cornerstone of modern orthobiologics.
In my practice, I’ve witnessed the transformation of orthobiologics from a niche adjunct into a disciplined, evidence-based arena. Ten years ago, orthobiologics research often relied on heterogeneous methods, limited standardization, and sparse comparative data. Today, with organizations such as the Interventional Orthobiologics Foundation and the Biologics Association spearheading research quality, we’re seeing thoughtful protocols anchored in patient-reported outcomes, validated measures, and preclinical bench research that clarifies mechanisms of action.
The most significant implication of this maturation is the ability to offer patients credible, non-surgical options with realistic expectations of benefit. For many musculoskeletal presentations formerly funneled toward surgery or serial corticosteroid injections, orthobiologics now offer a pathway to correct underlying pathophysiology earlier in the disease continuum, reduce pain, and support native tissue repair.
Autologous therapies use the patient’s own biologic materials—typically blood or bone marrow components—to mobilize repair mechanisms with lower immunogenic risk and context-appropriate signaling. The core rationale is straightforward: our tissues possess dormant regenerative capacity that can be awakened, focused, and amplified when the right signals and substrates are delivered to the right place.
Key benefits that I observe and target clinically include:
The clinical takeaway: autologous biologics deliver a biologically coherent repair signal. When we understand which signals benefit a particular tissue pathology—and how to deliver them with appropriate composition and dose—we can move beyond generic protocols and into precision biologic care.
Early in my journey, I admittedly considered PRP a kind of “magic dust.” That perception dissolves the moment you engage the basic science. PRP is blood—no more, no less—processed to concentrate platelets and associated bioactive factors. When those platelets degranulate, they release a timed cascade of growth factors and cytokines, stimulating local repair.
Core components in whole blood:
Centrifugation separates these by density:
Importantly, platelets straddle layers. Some remain in PPP above the buffy coat; others migrate into the upper RBC stack with neutrophils. This is why recovery is never 100%. It’s also why we design protocols that optimize both yield and composition for the intended application.
The physiologic rationale for PRP:
A question that frequently arises in both academic circles and clinical training is about the ideal composition of Platelet-Rich Plasma (PRP). Specifically, there has been a significant shift in thinking regarding the inclusion of red blood cells (RBCs). For years, the dogma was to produce the “purest” PRP possible, meaning it was leukocyte-poor and completely devoid of red blood cells. The fear was that RBCs, being pro-inflammatory, would induce a severe post-injection flare, causing unnecessary pain for the patient and potentially hindering the healing process.
However, as our understanding of the cellular dynamics within centrifuged blood has deepened, so has our strategy. The current movement, supported by emerging evidence, is toward the inclusion of a small fraction of the red blood cell layer in our PRP preparation. So, to answer the question directly: In my practice, am I consistently going into the red top of the RBC layer for every patient? The answer is nuanced, but generally, yes, I am. I fine-tune it based on the clinical context, but the default is to capture more of the vital cellular components that lie at that precious interface.
Let’s break down the science behind this decision: when we centrifuge whole blood to create PRP, the components separate by density. At the very bottom, we have the densest components: the red blood cells. Just above them sits a thin, whitish-tan layer known as the buffy coat. This layer is the treasure trove of regenerative medicine. It contains the vast majority of the platelets and leukocytes (white blood cells). Above the buffy coat is the straw-colored platelet-poor plasma (PPP).
The challenge is that these layers are not perfectly distinct. There is a gradient. The highest concentration of platelets and, importantly, the beneficial mononuclear cells—monocytes and lymphocytes—are located in the lower portion of the buffy coat, right at the interface with the red blood cell layer. Monocytes are critical precursors to macrophages, which are the master regulators of the healing process. They orchestrate the cleanup of damaged tissue (M1 phenotype) and then pivot to signal for tissue repair and regeneration (M2 phenotype). Lymphocytes also play a complex, immunomodulatory role in tissue healing.
If we are overly cautious and aspirate only the upper part of the buffy coat to avoid any red color, we are inevitably leaving behind the densest, and arguably most potent, platelets and a significant portion of these crucial mononuclear cells. The research is becoming increasingly clear: a higher concentration of platelets and mononuclear cells correlates directly with greater efficacy and a higher response rate in patients. Therefore, the modern approach involves carefully dipping the aspiration needle just into the top of that RBC layer. The goal isn’t to draw up a large volume of red blood cells, but to ensure we capture the entire buffy coat.
Even with this technique, the final RBC content in the PRP sample is remarkably low, typically less than one percent. So we face a clinical trade-off. Do I prefer a “cleaner” PRP with lower platelet and monocyte concentrations, or do I accept a minuscule number of RBCs to gain a significantly more potent and biologically active injectate? For me, the choice is clear. I will almost always opt for the higher concentration of platelets, monocytes, and lymphocytes.
Now, this doesn’t mean we ignore the potential for an inflammatory flare. For intra-articular injections, particularly in sensitive joints, there is a legitimate concern that even a small number of RBCs can increase hemarthrosis-like irritation and heighten the post-injection inflammatory response. This is where we must be strategic. The inflammatory flare is largely driven by pro-inflammatory cytokines such as Interleukin-1 (IL-1) and destructive enzymes such as Matrix Metalloproteinases (MMPs). The rationale for avoiding RBCs was precisely to minimize this inflammatory onslaught.
Fortunately, we now have sophisticated tools to counteract this. One of the most effective strategies I use is the concurrent injection of an autologous protein concentrate. This is created by passing platelet-poor plasma (PPP), a byproduct of the PRP preparation, through a specialized filter. This process concentrates the large, beneficial proteins naturally present in the plasma. Among these are powerful anti-inflammatory molecules, including Alpha-2-Macroglobulin (A2M) and Interleukin-1 Receptor Antagonist Protein (IRAP).
By combining our potent, cell-rich PRP with this protein concentrate, we can have the best of both worlds. We achieve powerful regenerative signaling through the high concentration of platelets and mononuclear cells, while simultaneously mitigating potentially excessive inflammatory side effects. We are neutralizing the very molecules (MMPs and IL-1) that underpinned the original fear of including red blood cells. This evidence-based, dual approach allows us to maximize the therapeutic potential of our injectate, leading to significantly better outcomes for our patients.
In my practice, I continually assess whether adding a protein concentrate (PC) to platelet-rich plasma (PRP) meaningfully improves outcomes for a given tissue target. The central question is not simply, “Does PC help?” but, “Does PC help here now, given this tissue’s mechanics, vascularity, and the patient’s clinical goals?” This decision hinges on biological context, mechanical load expectations, and joint volume constraints.
Bottom line: Intra-articular applications frequently benefit from PC adjuncts; tendinous applications often perform well with PRP alone—particularly in LE—unless clinical features and prior outcomes argue otherwise.
When administering orthobiologic injectables like PRP, one of the most critical factors for success and patient comfort is the injection volume. It’s a common misconception to think that “more is better.” In reality, each Joint in the human body is a distinct biomechanical environment with a specific synovial capacity. Exceeding this capacity, or over-distending the joint capsule, can be intensely painful in itself, creating iatrogenic pain that can be mistaken for a severe inflammatory flare or procedural failure. It can also potentially damage the delicate synovial lining. Therefore, a “one-size-fits-all” approach is not just suboptimal; it’s poor medical practice. My injection volumes are carefully tailored to the specific joint being treated, based on anatomical constraints and clinical experience.
Let’s walk through a general guideline of the volumes I use in my practice. Please remember these are starting points and can be adjusted based on patient size, the specific pathology, and intra-procedural feedback.
The knee and the glenohumeral Joint (shoulder) are considered large-volume synovial joints. They have a relatively lax and capacious joint capsule that can comfortably accommodate a larger volume of fluid.
The hip and ankle joints are more constrained and have a significantly smaller intra-articular volume compared to the knee or shoulder. Overfilling these joints can quickly lead to a painful pressure spike.
As we move to the smaller joints of the upper extremity, the permissible volumes decrease even further. These joints are intricate and have very little tolerance for excess fluid.
Adhering to these volume guidelines is crucial to procedural safety and efficacy. The goal is to deliver a therapeutic dose of the biologic directly to the target tissue without causing harm or undue discomfort from mechanical pressure.
A pivotal concept in modern regenerative orthopedics is treating the “joint as an organ.” This paradigm shift moves us away from the reductionist view of treating a single, isolated structure (e.g., only the cartilage inside the Joint) and towards a more holistic, functional approach. A joint is not merely two bones meeting; it is a complex, integrated system composed of cartilage, synovium, subchondral bone, the joint capsule, stabilizing ligaments, and the tendons and muscles that cross it. Pain and dysfunction often arise from a failure in multiple components of this system, not just one.
So, when a patient asks if the injection volumes I mentioned are just for the intra-articular space and if I use the rest of the PRP elsewhere, the answer is a resounding yes, absolutely. My approach is nearly always comprehensive. The volume I inject intra-articularly is specifically for that space. The remaining PRP or protein concentrate is then meticulously used to treat the extra-articular ligamentous and tendinous structures that are critical to the Joint’s stability and function.
This is what some refer to as the functional joint unit approach. For example, when treating a knee, I don’t just inject into the joint space. I will also assess and treat the medial collateral ligament (MCL), the lateral collateral ligament (LCL), the pes anserine tendons, and the patellar tendon if they are tender, lax, or show pathology on diagnostic ultrasound. In the shoulder, this means addressing the rotator cuff tendons, the coracoacromial ligament, and the capsular ligaments.
This comprehensive strategy is especially vital for patients with any form of joint instability. This is particularly true for my patients with Ehlers-Danlos Syndrome (EDS) or other hypermobility spectrum disorders. In these individuals, the primary pathology is often ligamentous laxity. The ligaments, which act as the Joint’s static stabilizers, are too stretchy and fail to provide adequate support. This leads to micro-instability, chronic pain, and eventually, secondary damage to the cartilage and other structures. In these cases, simply injecting PRP into the joint space without addressing the failing ligaments is treating a symptom, not the root cause. My protocol involves a thorough evaluation of the joint capsule and all relevant ligaments, followed by targeted injections (prolotherapy-style) into these structures to stimulate a fibroblastic response, encouraging them to tighten and strengthen over time.
By treating the entire functional unit—the Joint and its supporting soft tissues—we create a more stable and biomechanically sound environment. This not only addresses multiple pain generators simultaneously but also protects the intra-articular environment from the ongoing damage caused by instability. It is a more thorough, more logical, and ultimately, more effective way to achieve long-term positive outcomes for our patients.
In my clinic, I employ a single-spin, benchtop processing workflow designed to balance simplicity and control. The goals are consistent platelet recovery, adjustable leukocyte content, and reproducible volumes tailored to the target tissue.
Workflow fundamentals:
Why each step matters:
Leukocyte modulation:
Example data from my clinic:
Why dose matters:
Color and RBC content:
The topic of local anesthesia in regenerative procedures requires careful consideration. The primary goal of our PRP injection is to initiate a robust, natural inflammatory and healing cascade. Certain local anesthetics, particularly those in the “-caine” family like Lidocaine and Bupivacaine, have been shown in laboratory studies to be chondrotoxic (toxic to cartilage cells) and potentially myotoxic (toxic to muscle cells). There is also evidence to suggest they can impair platelet function and blunt the very inflammatory response we are trying to create. Therefore, the decision of whether, when, and what type of anesthetic to use is not trivial. My protocol is designed to maximize patient comfort while minimizing potential interference with the treatment’s biological efficacy.
My approach to local anesthesia is bifurcated, depending on the location of the injection:
For injections that are purely intra-articular (inside the joint capsule), I do not use any local anesthetic mixed in with the PRP. The primary reason is to avoid any potential chondrotoxic effects on the cartilage we are trying to heal and to prevent any blunting of the platelet-driven healing cascade. Patients generally tolerate intra-articular injections well, as the joint space itself has relatively few nerve endings compared to the surrounding soft tissues. The discomfort is brief and manageable.
The situation is entirely different for extra-articular injections, which involve treating tendons, ligaments, and other soft tissues. These structures are richly innervated, and injections into them can be quite painful. My goal is to ensure the patient has a tolerable experience and walks out of the office not cursing my name. I’ve learned from experience that performing extensive extra-articular work without any anesthetic can be an excruciating experience for the patient, which can create anxiety about future treatments and follow-up.
For these soft tissue applications, I use a very low-dose, low-volume ropivacaine. Specifically, I use a 0.125% concentration by volume. I choose ropivacaine for several reasons. First, studies suggest it is less chondrotoxic and myotoxic compared to bupivacaine and lidocaine. Second, it has a longer duration of action, providing the patient with sustained relief for several hours after they leave the clinic. The concentration is key. By using a very dilute 0.125% solution, I am aiming for a sensory block (pain relief) without a significant motor block and, importantly, minimizing the total anesthetic dose to limit any potential negative impact on the regenerative process. This small amount of relief makes the procedure vastly more tolerable, improving the overall patient experience without, in my clinical experience, compromising the excellent outcomes we see.
So, to summarize my protocol:
This balanced approach respects the biology of the treatment while also respecting the patient’s need for a comfortable and positive clinical experience.
One of the most important concepts to communicate to patients undergoing PRP therapy is the nature of the post-injection experience. A common question I get is, “How can we mitigate the inflammatory flare response?” This question often comes from a place of fear, as both patients and practitioners are conditioned to view inflammation as something negative that must be suppressed. However, in the context of regenerative medicine, this view is fundamentally misguided.
The entire goal of injecting PRP is to restart the body’s natural healing cascade. Chronic injuries, like tendinopathy or osteoarthritis, are stuck. The normal healing process has stalled, often in a state of chronic, low-grade, degenerative inflammation. PRP acts as a powerful biological signal that essentially tricks the body into thinking a new, acute injury has occurred. This initiates a robust acute inflammatory response, which is the first and absolutely essential phase of healing.
Think about what happens when you sprain your ankle. It becomes swollen, red, warm, and tender. This is the acute inflammatory response in action. It’s the body rushing blood flow, growth factors, platelets, and immune cells to the area to clean up damage and lay the groundwork for repair. We want this to happen after a PRP injection. Suppressing this acute, productive inflammation with anti-inflammatory drugs would be like calling the fire department to an injury and then telling them to go home before they’ve put out the fire and cleared the debris.
So, when patients ask how we can “mitigate” the flare, my first step is education. I reframe the flare not as a side effect to be avoided, but as an indicator that the treatment is working. It’s a sign that we have successfully initiated the healing cascade. The sequence we are aiming for is: Acute Inflammation → Proliferation → Remodeling → Full Resolution and Tissue Healing. The PRP kickstarts this process.
That being said, we don’t want the patient to be in agony. The goal is not to eliminate the flare but to help the patient manage symptoms and potentially shorten the duration of the most uncomfortable phase. I use a multi-pronged approach for symptom relief and to support the healing process:
By combining patient education with these supportive therapies, we can successfully manage the post-procedural experience, ensuring the patient is comfortable while allowing the essential biological process of healing to unfold unimpeded.
The success of a regenerative medicine procedure begins long before the needle ever touches the skin. A thorough and meticulous pre-procedure protocol is essential to optimize the patient’s physiology for healing, set clear expectations, and ensure safety. My pre-procedure consultation is a non-negotiable, comprehensive discussion lasting at least 30 minutes. During this time, we leave no stone unturned. Here is a breakdown of the key components of my pre-procedure discussion and preparation instructions.
It is imperative to be transparent about the financial aspects of the procedure. Most regenerative medicine therapies are not covered by insurance.
A thorough pre-procedure protocol is the foundation for a successful outcome. It optimizes the patient’s biological canvas, manages risks, and establishes a strong, transparent therapeutic alliance.
To truly understand the application of these principles, let’s walk through a real-world case. This patient is a lovely dental assistant who presented with chronic right lateral epicondylitis, or “tennis elbow.” Her occupation involves repetitive wrist and forearm movements, a classic risk factor for this condition. Before seeing me, she had already tried a host of conservative treatments, including NSAIDs, counterforce braces, and acupuncture, with no lasting relief. Notably, she had undergone a single PRP injection previously, but it was performed “blind” (without ultrasound guidance), and she was unsure of the cell dose or concentration she received. Her continued pain suggested the previous treatment was either misplaced, under-dosed, or both.
The first step is always a thorough diagnostic ultrasound examination. This allows me to visualize the anatomy in real-time and confirm the diagnosis and the extent of the pathology. I have the patient lay supine with her arm resting comfortably. After palpating the area of maximal tenderness over the lateral epicondyle, I place the ultrasound transducer in a long-axis orientation relative to the common extensor tendon.
What we immediately see on the screen is a classic picture of severe tendinopathy. The normal, bright, fibrillar pattern of a healthy tendon is replaced by dark, hypoechoic areas, particularly at the insertion point on the lateral epicondyle. This hypoechogenicity represents a disorganized, degenerative, and sometimes fluid-filled or torn tissue. In her case, the pathology is significant, indicating a substantial partial-thickness tear involving at least a third, and in some areas, up to two-thirds of the tendon’s thickness. This objective finding confirms that she is an excellent candidate for PRP and explains why her previous therapies failed.
After confirming the pathology, I plan my injection. I use an in-plane, long-axis approach, meaning the needle will be inserted parallel to the ultrasound transducer, and I will be able to see the entire length of the needle, from shaft to tip, throughout the procedure. My entry point will be from the right side of the screen (distal to the elbow), advancing the needle toward the epicondyle.
You can see on the video as I inject, the dark, torn area begins to fill with the PRP, lifting the tendon fibers apart. This confirms I am in the correct location. It is a large tear, and as I am performing the injection, I am having a conversation with the patient, managing expectations in real-time. I’ll say something like, “Wow, this is a pretty significant tear I’m seeing here. It’s important you are diligent with your post-procedure care. Some injuries of this size may require more than one treatment.”
By combining precise ultrasound guidance, advanced injection techniques like peppering and multi-planar views, and an evidence-based, therapeutic dose of platelets, we can transform a condition that has been refractory to multiple other treatments and offer the patient a genuine opportunity for complete and lasting healing.
The 48-72 hours following the procedure are just the beginning of the healing journey. A structured and comprehensive post-procedure protocol is essential for managing symptoms, supporting the biological process, and guiding the tissue back to full function. My post-procedure discussion is as detailed as my pre-procedure one, ensuring the patient is a well-informed and active participant in their own recovery.
As we’ve discussed, I educate the patient to expect significant tenderness and soreness for the first two to three days. This is the acute inflammatory phase, and it is a good sign. My strategy for managing this involves the Reparel® bioactive sleeve, MLS Laser therapy (with a goal of at least 12 sessions between injection and their formal follow-up), topical analgesics, and a short-term splint for nighttime use to rest the tendon.
A crucial aspect of my post-procedure instructions is the strict avoidance of certain substances:
The patient is not formally re-evaluated by me until eight weeks post-injection. This time frame is chosen deliberately. The biological healing cascade takes time. The initial inflammatory phase transitions into the proliferative phase (typically weeks 1-6), where the body begins to lay down new, disorganized collagen (Type III). This is followed by the remodeling phase (from week 6 up to a year or more), where this immature collagen is slowly replaced and reorganized into strong, mature, and aligned Type I collagen. Seeing a patient too early can be misleading, as significant healing is still underway.
However, “no follow-up for eight weeks” does not mean no contact. The patient has at least twelve touches with my team during their laser therapy sessions. My staff is trained to monitor their progress, answer questions, and escalate any concerns to me. We also use data collection tools to track their pain scores and functional improvement throughout this period.
Perhaps the most critical component of long-term success, especially for tendinopathy, is a structured rehabilitation program. I typically have my patients begin formal physical therapy about two weeks after the injection. We start with gentle range of motion exercises right away to prevent stiffness. However, the core of the rehab is the tendon rehab protocol.
I explain this to my patients as a “tendon training program.” Tendons are designed to withstand and transmit heavy loads. A healed tendon must be retrained to do its job effectively. The rehab protocol focuses on progressive eccentric and heavy slow resistance training.
This mechanical stress is not harmful; it is a vital signal. As we move through the proliferative and remodeling phases of healing, applying this controlled, progressive load guides the new collagen fibers to lay down in a highly organized, parallel alignment. This is what creates a tendon with high tensile strength, capable of resisting the forces of daily activity and sport. Without this mechanical guidance, the new tissue can heal as a disorganized scar, which is weak and prone to re-injury. The physical therapy program is essential for translating the biological healing initiated by the PRP into a functional, durable, and resilient tissue.
A critical part of managing patient expectations and clinical decision-making is having a clear follow-up and redosing strategy. When a patient undergoes a PRP procedure, a common question is, “When will I need to have this done again?” My honest answer is, “I hope never.” The goal and plan for a high-concentration, precisely delivered PRP injection is “one and done.” We aim to provide a sufficiently powerful stimulus to restart the healing cascade, leading to a durable, long-term resolution of the problem.
However, biology is complex, and not every patient responds in the same way. This is why having a clear benchmark for success is crucial. As I mentioned, my first formal clinical reassessment is at the eight-week mark post-injection. At this visit, I perform a thorough physical exam and, most importantly, I quantify the patient’s improvement. My key benchmark is a fifty percent (50%) improvement in pain and/or function by eight weeks.
This strongly suggests that many initial “failures” are not a failure of the patient to respond to the therapy, but rather a dosing problem. The initial dose may have been insufficient to overcome the catabolic environment of their chronic condition. When a patient asks what “redosing” means—if I use a double dose—the answer is no, I don’t change the concentration. I simply do it again. I administer another full, therapeutic dose of high-concentration PRP.
It is important to note that I do not tell my patients about this redosing option upfront. I don’t want to plant the seed in their mind that they will likely need two treatments. I want them to be fully committed to the goal of a single, successful procedure. However, I hold this option back as a clinical tool, at my discretion, for the subset of patients who show a partial but insufficient response at the eight-week mark. This strategy allows us to salvage a positive outcome for a significant number of patients who might otherwise be considered treatment failures.
Patient education: Expect tenderness early, respect tissue biology, and embrace graded loading. The outcome hinges as much on what happens post-injection as the injectate itself.
Shockwave therapy—both focused (fESWT) and radial (rESWT)—delivers controlled mechanical energy that can modulate pain and stimulate tissue regeneration. The decision to use shockwave post-PRP depends on the tissue’s mechanical resilience, structural integrity, and sensitization status.
In short, shockwave is a powerful tool, but only when tissue readiness and patient neurobiology align. The pairing with PRP is diagnosis-specific, stage-specific, and calibrated to the patient’s sensory profile.
Orthobiologics are not one-size-fits-all. I tailor PRP composition, volume, and injection technique to the target tissue:
In each scenario, I consider:
Device preparation:
Blood draw:
Centrifugation setup:
Post-spin processing:
Composition tuning:
Quality checks:
Rationale:
Throughout this discussion, I’ve mentioned the use of an adjunctive therapy: an autologous protein concentrate. This is a powerful tool in my regenerative toolbox, and it’s important to understand what it is and why I use it. A patient astutely asked for clarification on whether this was a specific protein like globulin. The answer is that it’s a concentrate of many large proteins naturally found in the patient’s own blood.
The product I use is derived through a system from Apex Biologics. The process begins with the platelet-poor plasma (PPP), which is the plasma left over after we’ve harvested the buffy coat to make our PRP. Instead of discarding this PPP, we can use it to create another valuable biologic. The PPP is pushed through a specialized, pre-wetted filter with a specific pore size of fifteen kilodaltons (15 kDa).
This filter works by a process of dehydration and size exclusion. Water and small molecules pass through the filter, but large proteins (those larger than 15 kDa) are retained and become highly concentrated. The result is a smaller volume of fluid that is super-concentrated with beneficial proteins. The two most important proteins that we concentrate with this method are:
I use this protein concentrate in two main ways. First, as discussed, I often co-inject it with PRP to help modulate the post-injection inflammatory flare by neutralizing MMPs and IL-1. Second, in some cases of pure osteoarthritis without significant ligamentous instability, I may use the protein concentrate as a standalone treatment. It provides a powerful anti-inflammatory and tissue-protective effect, making it an excellent option for patients who are primarily seeking pain relief and a slowing of degenerative changes. This advanced technique allows us to further customize our treatments, leveraging different components of the patient’s own blood to achieve specific biological goals.
Sustainable success in orthobiologics is not achieved through bold claims—it’s built through patient trust, regulatory compliance, and practice growth, each reinforcing the others.
This framework ensures that clinical decisions are scientifically defensible and that public communications are fair, accurate, and consistent with regulatory expectations—creating a durable foundation for your practice.
I categorize orthobiologic applications by regulatory and evidentiary risk:
Green Zone: Autologous biologics (e.g., PRP, bone marrow concentrate) processed with FDA-compliant methods and 510(k)-cleared devices, communicated using evidence-based language. Low regulatory risk when performed to standard-of-care.
Staying predominantly in the Green while thoughtfully engaging the Yellow empowers innovation without jeopardizing licensure or patient trust.
Transitioning from an insurance-driven orthopedic workflow to a cash-based orthobiologics practice has been transformative to the modern treatment protocols. Historically, doctors treated many patients daily, and the default pathway often involved physical therapy, corticosteroid injections, “come back when it’s worse,” or surgery. With orthobiologics, I can serve the majority of non-surgical patients—often 75–90% of an orthopedic caseload—with proactive, regenerative care.
Why this model adds value:
Ethically, this model demands:
Date of Content Creation: June 11, 2026
This educational post, presented from my perspective as Dr. Jimenez, DC, FNP-APRN, provides a deep and comprehensive exploration of advanced Platelet-Rich Plasma (PRP) therapy. On June 11, 2026, I prepared this synthesis to clarify how I utilize PRP, protein concentrates, laser therapy, and shockwave therapy in musculoskeletal care with an emphasis on ethical, compliant practice growth. We challenged the old paradigm of avoiding red blood cells (RBCs) in PRP, explaining the modern rationale for including the top of the RBC layer to maximize the harvest of platelets and crucial mononuclear cells. We discussed mitigating the inflammatory flare by using autologous protein concentrates rich in A2M and IRAP.
We then detailed the importance of tailoring injectate volumes to specific joints, providing guidelines for large (knee, shoulder), medium (hip, ankle), and small (elbow, wrist, digits) joints. This led to a discussion of the “joint as an organ” concept, emphasizing a comprehensive approach that treats the entire functional joint unit. For lateral epicondylitis, PRP alone is often sufficient, supported by staged isometric-to-eccentric loading. In small joints, I use a 3:1 or 4:1 PRP-to-PC ratio; in large joints, I may employ 1:1. We also covered my detailed pre- and post-procedure protocols, reframing the inflammatory flare as a positive sign of healing and outlining a multi-modal strategy for symptom management.
A significant portion was dedicated to practice management and ethics. The shift to a cash-based model restores autonomy and continuity of care. Ethically scaling an orthobiologics practice relies on the three-legged stool of patient trust, regulatory compliance, and practice growth. The FDA governs products/devices; the FTC governs claims; state boards oversee professional conduct. I advocate the Green/Yellow/Red risk framework: prioritize autologous biologics with compliant devices, document off-label rationales robustly, and avoid unapproved products. Finally, we clarified my follow-up and redosing strategy, using the 50% improvement mark at eight weeks as a key benchmark for deciding whether a second injection is warranted.
The field of regenerative medicine is in a constant state of evolution, driven by modern, evidence-based research and a deeper understanding of cellular physiology. The successful application of therapies like PRP extends far beyond simply injecting a patient’s own platelets back into them. The most effective orthobiologic care marries precise tissue-specific protocols with transparent, compliant communication. By embracing concepts like cell-dosing, treating the functional joint unit, and strategically managing the inflammatory response, we can move beyond simply managing symptoms and offer our patients a genuine opportunity for true tissue regeneration and lasting functional restoration. In practice strategy, compliance is a differentiator. Being the most trusted voice, grounded in evolving evidence and ethical clarity, outperforms loud marketing in the long run. The goal is always a durable, “one-and-done” outcome, and the principles outlined here provide a robust framework for achieving that goal.
Disclaimer: The information provided in this educational post is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. This content reflects the clinical experience and knowledge of Dr. Jimenez, DC, FNP-APRN, as of the content creation date (June 11, 2026), and is based on evidence and practices that are constantly evolving. It should not be used as a personal medical guide.
Disclaimer for Individual Medical Advice: All individuals are unique, and medical conditions vary. You must consult with your own qualified medical provider for any health concerns or before making any decisions related to your health or treatment. The protocols and opinions expressed in this post are generalized and may not be appropriate for your specific situation. Do not disregard, avoid, or delay obtaining medical advice from a qualified healthcare professional because of something you have read here. Reliance on any information provided in this post is solely at your own risk.
General Disclaimer, Licenses and Board Certifications *
Professional Scope of Practice *
The information herein on "Advanced PRP Science, Autologous Therapies, and Updated Practice Innovations" is not intended to replace a one-on-one relationship with a qualified health care professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional.
Blog Information & Scope Discussions
Welcome to El Paso's Premier Wellness and Injury Care Clinic & Wellness Blog, where Dr. Alex Jimenez, DC, FNP-C, a Multi-State board-certified Family Practice Nurse Practitioner (FNP-BC) and Chiropractor (DC), presents insights on how our multidisciplinary team is dedicated to holistic healing and personalized care. Our practice aligns with evidence-based treatment protocols inspired by integrative medicine principles, similar to those on this site and on our family practice-based chiromed.com site, focusing on naturally restoring health for patients of all ages.
Our areas of multidisciplinary practice include Wellness & Nutrition, Chronic Pain, Personal Injury, Auto Accident Care, Work Injuries, Back Injury, Low Back Pain, Neck Pain, Migraine Headaches, Sports Injuries, Severe Sciatica, Scoliosis, Complex Herniated Discs, Fibromyalgia, Chronic Pain, Complex Injuries, Stress Management, Functional Medicine Treatments, and in-scope care protocols.
Our information scope is multidisciplinary, focusing on musculoskeletal and physical medicine; wellness; contributing etiological viscerosomatic disturbances within clinical presentations; associated somato-visceral reflex clinical dynamics; subluxation complexes; sensitive health issues; and functional medicine articles, topics, and discussions.
We provide and present clinical collaboration with specialists from various disciplines. Each specialist is governed by their professional scope of practice and licensure jurisdiction. We use functional health & wellness protocols to treat and support care for musculoskeletal injuries or disorders.
Our videos, posts, topics, and insights address clinical matters and issues that directly or indirectly relate to our clinical scope of practice.
Our office has made a reasonable effort to provide supportive citations and has identified relevant research studies that support our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We understand that we cover matters that require an additional explanation of how they may assist in a particular care plan or treatment protocol; therefore, to discuss the subject matter above further, please feel free to ask Dr. Alex Jimenez, DC, APRN, FNP-BC, or contact us at 915-850-0900.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez DC, MSACP, APRN, FNP-BC*, CCST, IFMCP, CFMP, ATN
email: coach@elpasofunctionalmedicine.com
Multidisciplinary Licensing & Board Certifications:
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-State Advanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-state Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified: 1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 *
Colorado License #: C-APN.0105610-C-NP, Verified: C-APN.0105610-C-NP
New York License #: N25929, Verified N25929
License Verification Link: Nursys License Verifier
* Prescriptive Authority Authorized
ANCC FNP-BC: Board Certified Nurse Practitioner*
Compact Status: Multi-State License: Authorized to Practice in 40 States*
Graduate with Honors: ICHS: MSN-FNP (Family Nurse Practitioner Program)
Degree Granted. Master's in Family Practice MSN Diploma (Cum Laude)
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
(Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director
Digital Business Card
Dr. Maria Cardenas, MD
(Board Certified: Internal Medicine)
(Licensed Medical Doctor)
Medical Director, Clinical Director & Collaborative Physician
NPI # 1164426749
MD License #: J2933
Licenses and Board Certifications:
MD: Medical Doctor
DC: Doctor of Chiropractic
APRNP: Advanced Practice Registered Nurse
FNP-BC: Family Practice Specialization (Multi-State Board Certified)
RN: Registered Nurse (Multi-State Compact License)
CFMP: Certified Functional Medicine Provider
MSN-FNP: Master of Science in Family Practice Medicine
MSACP: Master of Science in Advanced Clinical Practice
IFMCP: Institute of Functional Medicine
CCST: Certified Chiropractic Spinal Trauma
ATN: Advanced Translational Neutrogenomics
Memberships & Associations:
TCA: Texas Chiropractic Association: Member ID: 104311
AANP: American Association of Nurse Practitioners: Member ID: 2198960
ANA: American Nurse Association: Member ID: 06458222 (District TX01)
TNA: Texas Nurse Association: Member ID: 06458222
NPI: 1205907805
| Primary Taxonomy | Selected Taxonomy | State | License Number |
|---|---|---|---|
| No | 111N00000X - Chiropractor | NM | DC2182 |
| Yes | 111N00000X - Chiropractor | TX | DC5807 |
| Yes | 363LF0000X - Nurse Practitioner - Family | TX | 1191402 |
| Yes | 363LF0000X - Nurse Practitioner - Family | FL | 11043890 |
| Yes | 363LF0000X - Nurse Practitioner - Family | CO | C-APN.0105610-C-NP |
| Yes | 363LF0000X - Nurse Practitioner - Family | NY | N25929 |
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
(Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director
Digital Business Card
Dr. Maria Cardenas, MD
(Board Certified: Internal Medicine)*
(Licensed Medical Doctor)*
Medical Director, Clinical Director & Collaborative Physician
NPI # 1164426749
MD License #: J2933
📆 Schedule Appointment: Schedule 24/7 (Click Here)
By Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
By: Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
Back Pain and Joint Stiffness: Laser Therapy Benefits Abstract In this educational post, I walk… Read More
by Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
El Paso Auto Accidents: The Hidden Dangers of Extreme Heat Extreme heat is more than… Read More
By Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST Read More
Personal Injury, Trauma & Spine Rehab. Specialists